Two Co-occurring Driver Mutations in Primary Lung Adenocarcinoma - Who's Driving Treatment?

Explore a 14-minute conference talk from the 2022 Cancer Genomics Consortium Annual Meeting that delves into the complexities of co-occurring driver mutations in primary lung adenocarcinoma. Gain insights into non-small cell lung carcinomas, driver mutations, and the RAS signaling pathway. Examine KRAS and BRAF mutations, including BRAF mutation classes. Follow two case studies, analyzing their pathology and laboratory findings. Learn about clinical treatment approaches and updates for patients with multiple driver mutations. Understand the implications of co-occurring driver mutations on treatment decisions in lung adenocarcinoma. This presentation, delivered by Danielle Salari, recipient of the CGC 2022 Technologist Award, offers valuable knowledge for oncologists, pathologists, and researchers in the field of cancer genomics.

Intro
Non-small cell lung carcinomas
What are driver mutations?
RAS Signaling Pathway
KRAS Mutations
BRAF Mutations & Classes
Case #1 Pathology Findings
Case #1 Lab Findings
Case #2 pathology findings
Case #2 lab findings
Clinical Treatment and Update
Who's driving treatment? Two Co-occurring Driver Mutations in Primary Lung Adenocarcinoma
Acknowledgements